About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Trial of Myocet in Metastatic Breast Cancer

Trial of Myocet in Metastatic Breast Cancer

NCT00294996·105 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Sopherion Therapeutics

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Metastatic Her2+ Breast cancer by FISH analysis
No prior chemotherapy for metastatic disease
Measurable disease
normal left ventricular ejection fraction

You may not be if

prior doxorubicin treatment exceeding 300 mg/m2 or epirubicin exceeding 600 mg/m2
relapse within 12 months of completion of adjuvant trastuzumab, taxane or anthracycline therapy

The record

StatusUnknown

PhasePhase 3

Taking part363

StartedJan 2006

UpdatedMar 31, 2009

Conditions

Where105

Scripps Cancer Center Clinical Research
San Diego, California, United States
University of Colorado
Aurora, Colorado, United States
Northwest Hematology/Oncology Associates
Coral Springs, Florida, United States